Literature DB >> 27199202

Pharmacokinetic investigations of the marker active metabolites 4-methylamino-antipyrine and 4-amino-antipyrine after intramuscular injection of metamizole in healthy piglets.

A Burmańczuk1, C Kowalski1, M Giorgi2, H Owen3, T Grabowski4.   

Abstract

Metamizole (MT) is a pyrazolone nonsteroidal anti-inflammatory drug labelled for humans and animals. The aim of this study was to assess the pharmacokinetics of its active metabolites 4-methylamino-antipyrine (MAA) and 4-amino-antipyrine (AA) in male piglets after a single intramuscular injection of MT. Eight healthy male piglets were administered MT (100 mg/kg) intramuscularly. Blood was sampled at scheduled time intervals, and drug plasma concentrations evaluated by a validated HPLC method. MAA and AA plasma concentrations were quantitatively detectable from 0.25 to 48 h and 0.50 to 72 h, respectively, in 6 of 8 and 7 of 8 animals. The average maximum concentrations of MAA and AA were of 47.59 and 4.94 mg/mL, respectively. The average half-lives were 8.57 and 13.3 h for MAA and AA, respectively. This study showed that the amount of MAA and AA produced in piglets is different to that in the animal species previously investigated. Further studies are necessary to understand whether these differences in MAA and AA plasma concentrations between animal species necessitate diverse therapeutic drug dosing.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27199202     DOI: 10.1111/jvp.12317

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  2 in total

1.  The using of a piglets as a model for evaluating the dipyrone hematological effects.

Authors:  Artur Burmańczuk; Andrzej Milczak; Tomasz Grabowski; Monika Osypiuk; Cezary Kowalski
Journal:  BMC Vet Res       Date:  2016-11-25       Impact factor: 2.741

2.  Pharmacokinetics of metamizole (dipyrone) as an add-on in calves undergoing umbilical surgery.

Authors:  Daniela Fux; Moritz Metzner; Johanna Brandl; Melanie Feist; Magdalena Behrendt-Wippermann; Anne von Thaden; Christine Baumgartner
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.